Johnson & Johnson

Firefly

Biotech

J&J makes $1B bet on emerging DAC space by netting Firefly Bio

Johnson & Johnson has paid $1 billion upfront to buy itself a degrader antibody conjugate platform via the acquisition of Firefly Bio.

James Waldron Jun 8, 2026 10:05am

FDA

At CNPV hearing, industry support meets ‘concern’ from experts

Jun 5, 2026 5:00am

Robotic surgery

J&J’s Ottava surgical robot succeeds in gastric bypass study

May 6, 2026 2:10am

New road

J&J axes $5B CAR-T dream months after touting efficacy edge

May 1, 2026 8:26am

Lightbulb with an image of a brain inside

Johnson & Johnson teams up with Viz.ai on hematoma detection

Apr 22, 2026 9:00am

Close-up of human eye

Ray shines a light on $125M round targeting genetic eye therapy

Apr 21, 2026 10:33am